Perspective Therapeutics CATX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Perspective Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Perspective Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Perspective Therapeutics's stock-based comp?
- Perspective Therapeutics (CATX) reported stock-based comp of $2.55M in Q1 2026.
- How has Perspective Therapeutics's stock-based comp changed year-over-year?
- Perspective Therapeutics's stock-based comp increased by 21.7% year-over-year, from $2.1M to $2.55M.
- What is the long-term trend for Perspective Therapeutics's stock-based comp?
- Over 2 years (2023 to 2025), Perspective Therapeutics's stock-based comp has grown at a 54.9% compound annual growth rate (CAGR), from $3.74M to $8.97M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.